InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Monday, 04/29/2019 3:50:40 PM

Monday, April 29, 2019 3:50:40 PM

Post# of 7747
News: $CYTR CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S

LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (CPH: ORPHA) has completed enrollment in its Phase 2/3 clinical tria...

Find out more https://marketwirenews.com/news-releases/cytrx-corporation-highlights-enrollment-completion-in-phase-2-3-clinical-trial-of-sporadic-inclusion-body-myositis-conducted-by-arimoclomol-licensee-orphazyme-a-s-8075264.html